Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations.
作者信息
Azzollini Jacopo, Mariani Milena, Peissel Bernard, Manoukian Siranoush
机构信息
Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
出版信息
Fam Cancer. 2018 Jul;17(3):317-319. doi: 10.1007/s10689-017-0020-z.
Abstract
摘要
相似文献
1
Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations.
Fam Cancer. 2018 Jul;17(3):317-319. doi: 10.1007/s10689-017-0020-z.
2
p53 in breast cancer subtypes and new insights into response to chemotherapy.
Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005.
3
4
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Breast Cancer Res. 2007;9(3):R30. doi: 10.1186/bcr1675.
5
Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.
6
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.
7
TP53 and breast cancer.
Hum Mutat. 2003 Mar;21(3):292-300. doi: 10.1002/humu.10174.
8
Loop domain organization of the p53 locus in normal and breast cancer cells correlates with the transcriptional status of the TP53 and the neighboring genes.
J Cell Biochem. 2011 Aug;112(8):2072-81. doi: 10.1002/jcb.23129.
9
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411.
10
8-Oxo-7,8-dihydro-2'-deoxyguanosine and other lesions along the coding strand of the exon 5 of the tumour suppressor gene P53 in a breast cancer case-control study.
DNA Res. 2016 Aug;23(4):395-402. doi: 10.1093/dnares/dsw018. Epub 2016 Jun 2.
引用本文的文献
1
TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Fam Cancer. 2019 Apr;18(2):273-280. doi: 10.1007/s10689-018-00118-0.
本文引用的文献
1
Next generation sequencing is informing phenotype: a TP53 example.
Fam Cancer. 2018 Jan;17(1):123-128. doi: 10.1007/s10689-017-0002-1.
2
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.
J Clin Oncol. 2015 Jul 20;33(21):2345-52. doi: 10.1200/JCO.2014.59.5728. Epub 2015 May 26.
3
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.
4
Routine TP53 testing for breast cancer under age 30: ready for prime time?
Fam Cancer. 2012 Dec;11(4):607-13. doi: 10.1007/s10689-012-9557-z.
5
Breast cancer incidence trends in European women aged 20-39 years at diagnosis.
Breast Cancer Res Treat. 2012 Jul;134(1):363-70. doi: 10.1007/s10549-012-2031-7. Epub 2012 Mar 29.
6
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.
Fam Cancer. 2009;8(4):563-7. doi: 10.1007/s10689-009-9287-z.
Zotero 插件